Lupus (Systemic Lupus Erythematosus) and cannabis in Washington
The state currently does not list this condition as qualifying, and the program does not provide open-ended physician discretion to add conditions. Verify with the state regulator, because programs change.
- ✗ No
- LEGAL
- 3 oz flower / 48 oz inf…
- POSSESSION
- $1/yr
- STATE FEE
- 1–7 d
- TIMELINE
Washington statute and program
The Washington Medical Marijuana Authorization Database is the operating authority for Washington patient certification. The authoritative legal text is: Washington State Liquor and Cannabis Board: Medical Cannabis. The program portal is at Washington Medical Marijuana Authorization Database.
What the evidence says about cannabis and Lupus (Systemic Lupus Erythematosus)
Systemic lupus erythematosus (SLE), commonly called lupus, is a chronic autoimmune disease in which the immune system produces autoantibodies that attack the body's own tissues. Inflammation can affect joints, skin, kidneys, blood, lungs, heart, and the nervous system. Lupus is a relapsing-remitting disease — patients experience flares and periods of relative quiescence.
For the full evidence base, including the NASEM tier, randomized trial summaries, and symptom-domain breakdown, read the mmjnow Lupus (Systemic Lupus Erythematosus) page.
How to qualify in Washington
The Washington Medical Marijuana Authorization Database requires the following registration steps for a Lupus (Systemic Lupus Erythematosus) patient (or any qualifying diagnosis):
- Get authorization from a Washington-licensed healthcare practitioner. Under RCW 69.51A (Washington State Medical Use of Cannabis Act, originally I-692 of 1998), any Washington-licensed MD, DO, advanced registered nurse practitioner, physician assistant, or naturopath may issue an authorization. Qualifying terminal or debilitating conditions include cancer, HIV/AIDS, MS, epilepsy, Crohn’s, hepatitis C, glaucoma, intractable pain, severe nausea, severe muscle spasms, anorexia (cachexia), traumatic brain injury, and PTSD.
- Enter the Medical Marijuana Authorization Database at a recognition card-issuing dispensary. Washington moved to a unified retail model in 2016 (under 2SSB 5052) — there are no medical-only dispensaries. A patient takes the practitioner authorization to any state-licensed cannabis retailer with a medical endorsement (about 60% of WA retailers). The retailer’s medically endorsed Consultant enters the patient into the Washington State Department of Health Medical Marijuana Authorization Database (MMAD) and issues a Medical Marijuana Recognition Card.
- Pay the $1 recognition card fee. Washington charges a nominal $1 fee for the Medical Marijuana Recognition Card itself (paid to the database vendor). Patients pay only this nominal fee plus the practitioner authorization fee — the practitioner fee is the dominant cost. There is no separate state patient registration fee. Caregivers ("designated providers") are added through the same database without an additional state fee.
- Purchase tax-free from a medically endorsed Washington retailer. With the Recognition Card and a Washington driver license or state ID, patients may purchase from any of the medically endorsed Washington licensed cannabis retailers (state-licensed I-502 retailers with the additional medical endorsement). The Recognition Card exempts the patient from Washington’s 37% retail cannabis excise tax — one of the most valuable medical-program benefits in any state. Patients may possess up to 3 ounces of usable cannabis (vs. 1 ounce adult-use) and may cultivate up to 6 plants. Washington does not honor out-of-state medical cards.
- State registration fee
- $1
- Physician visit (typical)
- $150–$300
- Certification to card
- 1–7 days
- Out-of-state patients
- Not eligible
- Minors
- Eligible with caregiver
For full Washington registration steps, fees, and reciprocity rules, see the Washington cannabis-laws page.
ICD-10 code
A certifying physician documenting Lupus (Systemic Lupus Erythematosus) for the Washington medical cannabis program will typically record ICD-10 M32.9 or SNOMED-CT 55464009 in the patient's record. The state registry does not itself collect ICD-10 codes in most programs, but the physician's chart is the audit trail if the certification is later reviewed.
Frequently asked questions
Does Washington list Lupus (Systemic Lupus Erythematosus) as a qualifying condition for medical cannabis?
No. Washington's qualifying-condition list does not currently include Lupus (Systemic Lupus Erythematosus), and the state's program does not give physicians open-ended discretion to add conditions outside the list. Patients with Lupus (Systemic Lupus Erythematosus) in Washington have limited in-state pathways under the medical program as written. Options to verify and pursue include: petitioning the state regulator to add the condition (where the statute permits public petitions); consulting a physician about whether a co-occurring listed condition could support certification; or reviewing whether the state's program is undergoing legislative expansion. Washington program rules change, so verify the current list with the regulator before drawing a final conclusion.
How do I get a Washington medical marijuana card for Lupus (Systemic Lupus Erythematosus)?
Because Washington does not currently list Lupus (Systemic Lupus Erythematosus) as a qualifying condition, a card for Lupus (Systemic Lupus Erythematosus) alone may not be obtainable in-state under the program rules as written. Step one is finding a physician licensed in Washington who is registered with Washington Medical Marijuana Authorization Database and willing to evaluate Lupus (Systemic Lupus Erythematosus) cases. Step two is collecting your records (diagnosis documentation, treatment history, and the ICD-10 code your physician will use) and bringing them to the certification visit. Step three is the physician's certification through the state registry, followed by the patient registration application, state fee, and waiting period before the card is issued. Washington does not honor out-of-state cards, so the certification process has to originate inside the state. Verify the patient minimum age with the state program before applying. The authoritative source for the current process is the Washington Medical Marijuana Authorization Database site at https://www.doh.wa.gov/YouandYourFamily/Marijuana/MedicalMarijuana; the state updates fees, forms, and physician registration rules periodically.
What does the evidence say about cannabis for Lupus (Systemic Lupus Erythematosus)?
For Lupus (Systemic Lupus Erythematosus), evidence is described as limited (a small number of supportive studies, often underpowered or focused on narrow symptom domains). The mmjnow condition page for Lupus (Systemic Lupus Erythematosus) lays out the current evidence base, including the citations underlying that evidence tier — typically the National Academies of Sciences, Engineering, and Medicine consensus reports, federal agency guidance, and peer-reviewed reviews. Evidence quality is independent of state law: a state can list a condition for which evidence is limited, and a state can decline to list a condition for which evidence is strong. Patients deciding whether to pursue medical cannabis for Lupus (Systemic Lupus Erythematosus) should review the underlying evidence (linked on the condition page) and discuss expected benefit, dosing, and risk with a clinician familiar with both Lupus (Systemic Lupus Erythematosus) and cannabinoid pharmacology. Cannabis is not a substitute for evidence-based first-line treatments for Lupus (Systemic Lupus Erythematosus); the evidence position above describes whether trial data supports its use, not whether it should replace standard care.
Sources
- Washington State Liquor and Cannabis Board: Medical Cannabisaccessed May 16, 2026
- Washington State Department of Health: Medical Cannabisaccessed May 14, 2026
- NIH National Institute of Arthritis and Musculoskeletal and Skin Diseases: Lupusaccessed May 18, 2026
- NASEM: The Health Effects of Cannabis and Cannabinoids (2017)accessed May 18, 2026
“Substantial evidence that cannabis or cannabinoids are effective for chronic pain in adults.”
- Lupus Foundation of America: Marijuana and Lupusaccessed May 18, 2026
- American College of Rheumatology: 2023 Guideline for SLE Management (executive summary)accessed May 18, 2026
- MedlinePlus: Systemic lupus erythematosusaccessed May 18, 2026